LOS ANGELES–(COMMERCIAL LINE). to three new non-executive employees.
The bonuses were awarded as part of Puma’s 2017 Employment Incentive Plan, adopted on April 27, 2017 and which provides for the granting of equity bonuses to new Puma employees. The award of restricted shares accrues over a three-year period, with one third of the shares underlying each award accruing on the first anniversary of the award commencement date, May 1, 2022, and one sixth of the underlying shares to each bonus accrues every six months from the start date of the next accrual, subject to continuity of service. The awards were given as an incentive material to new employees who started working with Puma, in accordance with Nasdaq Listing Rule 5635 (c) (4).
Information on Puma biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products to improve cancer care. Puma licenses global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with HER2 overexpressed / amplified early stage breast cancer following adjuvant trastuzumab therapy, and is marketed in the United States such as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX obtained marketing authorization from the European Commission in 2018 for the extended adjuvant treatment of adult patients with HER2 overexpressed / hormone receptor amplified breast cancer in early stage and less than one year after completion of prior adjuvant therapy based on trastuzumab. NERLYNX is a registered trademark of Puma Biotechnology, Inc.